Dermira discontinues development of acne candidate
Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor of acetyl-Coenzyme A carboxylase (ACAC; ACC).
The 759-patient CLAREOS-1 and 744-patient CLAREOS-2 trials’ co-primary endpoints measured inflammatory and non-inflammatory lesion counts in patients ages nine and older, and compared twice-daily topical 5% olumacostat with vehicle for 12 weeks. A third co-primary endpoint measured the proportion of patients with a ≥2-grade improvement and a final grade of 0 or 1 point on the 5-point Investigator’s Global Assessment (IGA) scale. Secondary endpoints included the percentage change in inflammatory and non-inflammatory lesion counts on the face at 12 weeks...